New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
11:43 EDTOCN, GGB, MYL, KMPOptions with increasing implied volatility: OCN GGB MYL KMP
News For OCN;GGB;MYL;KMP From The Last 14 Days
Check below for free stories on OCN;GGB;MYL;KMP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
14:52 EDTOCNOcwen Financial management to meet with Sterne Agee
Subscribe for More Information
14:51 EDTOCNOcwen Financial management to meet with Piper Jaffray
Subscribe for More Information
August 29, 2014
15:29 EDTMYLMylan receives FDA approval for generic lamivudine, aidovudine
Subscribe for More Information
August 28, 2014
11:22 EDTMYLMylan ANDA for three times per week generic Copaxone accepted by FDA for filing
Mylan (MYL) announced that its abbreviated new drug application for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration. This product is the generic version of Teva's (TEVA) Copaxone 40 mg/mL, which is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval. Copaxone 40 mg/mL had U.S. sales of approximately $411.5M for the 12 months ending June 30, 2014, according to IMS Health.
August 25, 2014
12:41 EDTKMPKinder Morgan receives Hart-Scott-Rodino clearance
Kinder Morgan (KMI) announced the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Kinder Morgan Energy Partners (KMP). The proposed acquisition was announced on Aug. 10, along with the proposed acquisitions of Kinder Morgan Management (KMR) and El Paso Pipeline (EPB), for which no HSR filings were required. The approximately $70B transaction is expected to close by the end of 2014 following unitholder and shareholder votes, and standard regulatory notifications and approvals.
August 22, 2014
08:02 EDTMYLMylan launches first generic Klor-Con Extended-release tablets
Subscribe for More Information
August 20, 2014
11:44 EDTMYLMylan completes second bidding round for GSK prescription portfolio, WSJ says
Mylan (MYL), TPG Capital, Advent International, KKR (KKR), Warburg Pincus and a few Indian prescription manufacturers have completed the second round of bidding for GlaxoSmith Kline's (GSK) portfolio of mature medications, according to The Wall Street Journal, citing people familiar with the sales process. GSK noted that it aims to sell a portfolio of drug brands in the U.S. and EU with yearly sales of approximately $1.66B. Reference Link
11:33 EDTMYLMylan into second round of bidding for GSK drug portfolio, WSJ reports
Subscribe for More Information
06:46 EDTOCNSEC sought information on Ocwen Financial's ties to other firms, NY Times says
Ocwen Financial has received a subpoena from the SEC for documents relating to other companies with which it does business, the company reported in a regulatory filing earlier this week, according to The New York Times. The executive chairman of Ocwen, William Erbey, is chairman of some of these other companies, the newspaper stated. Reference Link
August 19, 2014
11:44 EDTMYLMylan launches generic Precedex Injection
Subscribe for More Information
07:07 EDTKMPKinder Morgan price target raised to $45 from $40 at RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use